← 返回前沿论文

宫颈癌 TIL(肿瘤浸润淋巴细胞)治疗的研究进展

英文原题:Research progress on tumor-infiltrating lymphocyte therapy for cervical cancer.

PubMed 2025/05/19(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

研究概要

宫颈癌是女性常见的恶性肿瘤,人乳头瘤病毒(HPV)感染是宫颈癌的主要原因。

中文摘要

宫颈癌是女性常见的恶性肿瘤,人乳头状瘤病毒(HPV)感染是宫颈癌的主要病因。TIL(肿瘤浸润淋巴细胞)(TILs)是主要存在于肿瘤实质和间质中、以T淋巴细胞为主的异质性淋巴细胞群,可自肿瘤组织中分离,经体外激活、扩增后回输给患者,发挥抗肿瘤免疫作用。作为一种个体化免疫治疗,TILs疗法在晚期复发、转移性宫颈癌中显示出令人满意的疗效和安全性,为晚期宫颈癌患者带来了新希望。但TILs疗法在晚期宫颈癌治疗中仍面临诸多局限与挑战。本文就TILs疗法在晚期宫颈癌中的治疗流程及最新进展进行综述,并探讨其应用挑战与前景。

展开英文摘要原文

Cervical cancer is a common malignant tumor in women, and human papillomavirus (HPV) infection is a major cause of cervical cancer. Tumor-infiltrating lymphocytes (TILs) are a heterogeneous group of lymphocytes primarily composed of T lymphocytes found within the tumor parenchyma and stroma. These cells can be isolated from tumor tissue, activated, expanded in vitro , and reinfused into the patient to exert an anti-tumor immune effect. As a form of personalized immunotherapy, TILs therapy has shown satisfactory efficacy and safety in advanced recurrent and metastatic cervical cancer, offering new hope to patients with advanced cervical cancer. However, TILs therapy for advanced cervical cancer still faces several limitations and challenges. This article reviews the process and latest developments in TILs therapy for advanced cervical cancer and discusses the challenges in the usage and prospects for this treatment.

论文信息

作者
Zhang W、Liu YM、Li D、Liu S、Cai XJ、Tang JY、Zuo ZG、Li XH
单位
Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.China
文献类型
综述
期刊
Frontiers in immunology2025
原文标识
PubMed 40458394 · DOI 10.3389/fimmu.2025.1524842